Live Breaking News & Updates on Novel Therapy

Stay updated with breaking news from Novel therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Relapsed/Refractory Follicular Lymphoma Treatment Armamentarium

Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting. ....

Sameh Gaballa , Matthew Lunning , Treatment Approach , Expanding Treatment Options , Refractory Follicular Lymphoma , Follicular Lymphoma , Relapsed Refractory Fl , Relapsed Refractory Follicular Lymphoma , Fl Cancer , Bendamustine Obinutuzumab , Pr Squared , Lenalidomide Rituximab , R Chop , R Cvp , Cart Therapy , Cart Cell Therapy , Auto Transplant Consolidation , Transplant Consolidation , Novel Therapy , Combination Therapy , Clinical Trials ,

Clinical Data With Lurbinectedin in Small Cell Lung Cancer

Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy. ....

Evolving Paradigms , Data With Lurbinectedin , Small Cell Lung , Small Cell Lung Cancer , Limited Stage Sclc , Extensive Stage Sclc , Ls Sclc , Es Sclc , Second Line Therapy , Second Line Treatment , Imforte Trial , Imforte Study , Platinum Resistant , Platinum Sensitive , Maintenance Therapy , Adverse Events , Drug Adverse Event , Toxicity Profile , Safety Profile , Lagoon Trial , Lagoon Study , Novel Therapy , Combination Therapy , Clinical Trials ,

Optimizing Real-World Ponatinib Use in Ph+ ALL: Treatment Considerations

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS. ....

Hagopm Kantarjian , Bijald Shah , Acute Lymphoblastic Leukemia , Call Cancer , Oph All , Ph Acute Lymphoblastic Leukemia , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Newly Diagnosed All , Newly Diagnosed Acute Lymphoblastic Leukemia , Ponatinib Based Therapy , Ponatinib Safety , Ponatinib Efficacy , Ponatinib Dose Adjustment , Blinatumomab Combination , Molecular Response , Cns Relapse , Allogeneic Stem Cell Transplantation , Fda Approval Of Ponatinib , Ponatinib Approval , Ikaros Positive , Combination Therapy , Novel Therapy ,

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment. ....

Bijal Shah , Hagop Kantarjian , Expert Insights , Newly Diagnosed , Frontline Therapy , Acute Lymphoblastic Leukemia , Call Cancer , Oph All , Ph Acute Lymphoblastic Leukemia , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Newly Diagnosed All , Newly Diagnosed Acute Lymphoblastic Leukemia , Tki Therapy , Comparative Trials , Hypercvad Therapy , Broad Acting Tki , Compound Mutations , Phallcon Study , Phallcon Trial , Low Intensity Chemotherapy , Imatinib Therapy , Ponatinib Therapy , Dasatinib Therapy , Novel Therapy , Combination Therapy ,

Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma. ....

Unmet Needs , Provide Optimal Care , Multiple Myeloma , Newly Diagnosed Multiple Myeloma , Frontline Therapy , First Line Therapy , First Line Treatment , Combination Therapy , Triplet Therapy , Quadruplet Therapy , Maintenance Therapy , Multiple Myeloma Transplant , Adverse Events , Safety Profile , Sequencing Therapy , Novel Therapy ,